title: [Treatment of clinically localized prostate cancer. Part II--efficiency comparison of therapy methods].
abstract: The optimal management of clinically localized (T1, T2) prostate cancer remains controversial. In response to these controversies the American Urological Association guidelines considered surgery, radiotherapy or watchful waiting to be options, because the literature does not provide clear evidence for the superiority of any one treatment. The aim of this paper is presentation of current knowledge regarding this problem.
authors.affiliation: Medical University of Wroclaw, Poland.
authors.forename: Jolanta
authors.initials: J
authors.lastname: Szelachowska
authors.forename: Jan
authors.initials: J
authors.lastname: Kornafel
authors.forename: Iwona
authors.initials: I
authors.lastname: Gisterek
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects; D002277:Carcinoma / Q000188:drug therapy / Q000453:epidemiology / Q000532:radiotherapy* / Q000601:surgery*; D018572:Disease-Free Survival; D006801:Humans; D008297:Male; D008875:Middle Aged; D011467:Prostate; D017430:Prostate-Specific Antigen / Q000097:blood; D011468:Prostatectomy / Q000009:adverse effects* / Q000706:statistics & numerical data; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000453:epidemiology / Q000532:radiotherapy* / Q000601:surgery*; D011788:Quality of Life; D016032:Randomized Controlled Trials as Topic / Q000706:statistics & numerical data; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D018931:Antineoplastic Agents, Hormonal; D017430:Prostate-Specific Antigen